



ASX ANNOUNCEMENT

25 January 2022

Cann granted GMP licence for Southern facility and inspected for Mildura GMP licence

25 January 2022 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce that it has achieved an important regulatory milestone for the Company with the Therapeutic Goods Administration (**TGA**) granting to Cann a GMP licence to manufacture therapeutic goods for its Southern facility (**Southern GMP Licence**).

The Southern GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredient (**API**) and medicinal cannabis products under cGMP conditions at its Southern facility for supply in Australia and overseas. This follows a significant upgrade of that facility which was substantially funded by the Company's successful capital raise in July and August last year.

Dried cannabis flower products produced under the Southern GMP Licence are expected to be available for supply to patients under the TGA's Special Access Scheme (**SAS**) and Authorised Prescriber (**AP**) scheme within the next few weeks.

Cann CEO, Peter Crock said: "Over the last 12 months, we have seen increasing demand for cGMP products from both domestic and international customers and have had pre-orders in place since late last year pending the granting of this licence. We are now able to service the needs of those customers. The granting of this licence is also another important achievement for Cann as we develop our integrated supply chain."

In further regulatory updates, Cann's Mildura facility was recently inspected by the TGA in respect of an application for a GMP licence to manufacture therapeutic goods and to undertake GMP testing at the Mildura site (**Mildura GMP Licence**).

The Mildura GMP Licence will, once granted, enable Cann to manufacture cannabis extract (**API**) and Cann's Satipharm CBD capsules. Additionally, the Mildura GMP Licence will allow Cann to operate a GMP certified chemical, physical and microbiological laboratory for analytical testing of cannabis dried flower and various medicinal products and excipients, being a critical in-house capability enabling Cann to demonstrate that products meet local and overseas regulatory requirements.

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com